Evidence map›Paper›PMID 28884423›Full record

Observational studyJournal of general internal medicine2017

Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts.

Russell P Bowler, Nadia N Hansel, Sean Jacobson, R Graham Barr, Barry J Make, MeiLan K Han, Wanda K O'Neal, Elizabeth C Oelsner, Richard Casaburi, Igor Barjaktarevic and 10 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of general internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Vaping-related lung disease: a narrative review.Journal of thoracic disease · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  18. Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 1 country.

Russell P BowlerUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA. BowlerR@NJHealth.org.
Nadia N HanselDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sean JacobsonNational Jewish Health, 1400 Jackson Street, Denver, CO, 80206, USA.
R Graham BarrDepartments of Medicine and Epidemiology, Columbia University Medical Center, New York, NY, USA.
Barry J MakeNational Jewish Health, 1400 Jackson Street, Denver, CO, 80206, USA.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Wanda K O'NealDepartment of Medicine, Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Elizabeth C OelsnerDepartments of Medicine and Epidemiology, Columbia University Medical Center, New York, NY, USA.
Richard CasaburiRehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Igor BarjaktarevicDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, California, Los Angeles, USA.
Chris CooperDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, California, Los Angeles, USA.
Marilyn ForemanDepartment of Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dawn L DeMeoChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Edwin K SilvermanChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
William BaileyDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Kathleen F HarringtonDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Prescott G WoodruffDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine and Cardiovascular Research Institute, University of California San Francisco, School of Medicine, San Francisco, CA, USA.
M Bradley DrummondDepartment of Medicine, Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
for COPDGene and SPIROMICS Investigators
Brigham and Women's Hospital · USColumbia University Irving Medical Center · USJohns Hopkins University · USUniversity of California, Los Angeles · USUniversity of North Carolina at Chapel Hill · USNational Jewish Health · USThe Lundquist Institute · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Metabolomic signatures of empysema and COPD progression in the COPDGene cohortR01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2012 to 2016
$31.1M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
(2 of 2) Genetic Epidemiology of COPDR01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2012 to 2016
$18.9M
Metabolic profiles of COPD phenotypesP20HL113445 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL · 2012 to 2016
$4.7M
Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated EmphysemaR01HL130883 · NHLBI · UNIVERSITY OF IOWA · PI HOFFMAN, ERIC ALFRED · 2016 to 2020
$3.6M
Ultra-low Dose, High Speed, High Resolution, Multispectral, Multi-Source MDCT ScaS10OD018526 · OD · UNIVERSITY OF IOWA · PI HOFFMAN, ERIC ALFRED · 2015 to 2015
$2.0M
Metabolome and proteome profiles of emphysema and airway diseaseR01HL095432 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL · 2009 to 2012
$1.6M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
Hypercoagulability and Chronic Lung Disease in Older AdultsK23HL130627 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI OELSNER, ELIZABETH · 2016 to 2019
$686k
NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K23 HL130627NHLBI NIH HHS K24 HL137013NHLBI NIH HHS P20 HL113445NHLBI NIH HHS R01 HL089856NHLBI NIH HHS R01 HL089897NHLBI NIH HHS R01 HL095432NHLBI NIH HHS R01 HL130883NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL137880NIH HHS S10 OD018526
6 · The paper itself

Abstract

backgroundElectronic cigarettes (e-cigarettes) are battery-operated nicotine-delivery devices used by some smokers as a cessation tool as well as by never smokers.

objectiveTo determine the usage of e-cigarettes in older adults at risk for or with chronic obstructive pulmonary disease (COPD).

designProspective cohorts.

participantsCOPDGene (N = 3536) and SPIROMICS (N = 1060) subjects who were current or former smokers aged 45-80. MAIN MEASURES: Participants were surveyed to determine whether e-cigarette use was associated with longitudinal changes in COPD progression or smoking habits. KEY

resultsFrom 2010 to 2016, participants who had ever used e-cigarettes steadily increased to 12-16%, but from 2014 to 2016 current use was stable at ~5%. E-cigarette use in African-Americans (AA) and whites was similar; however, AA were 1.8-2.9 times as likely to use menthol-flavored e-cigarettes. Current e-cigarette and conventional cigarette users had higher nicotine dependence and consumed more nicotine than those who smoked only conventional cigarettes. E-cigarette users had a heavier conventional cigarette smoking history and worse respiratory health, were less likely to reduce or quit conventional cigarette smoking, had higher nicotine dependence, and were more likely to report chronic bronchitis and exacerbations. Ever e-cigarette users had more rapid decline in lung function, but this trend did not persist after adjustment for persistent conventional cigarette smoking.

conclusionsE-cigarette use, which is common in adults with or at risk for COPD, was associated with worse pulmonary-related health outcomes, but not with cessation of smoking conventional cigarettes. Although this was an observational study, we find no evidence supporting the use of e-cigarettes as a harm reduction strategy among current smokers with or at risk for COPD.

Indexed as

AdultAgedAged, 80 and overBronchitisCigarette SmokingCohort StudiesDisease ProgressionElectronic Nicotine Delivery SystemsFemaleHarm ReductionHumansLongitudinal StudiesMaleMiddle AgedPrevalencePulmonary Disease, Chronic ObstructiveCOPDelectronic cigarettelung functiontobacco

Identifiers

PMID28884423
PMCPMC5698219
OpenAlexW2752221041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.